Anti-tumor effect in an in vivo model by human-derived pancreatic RNase with basic fibroblast growth factor insertional fusion protein through antiangiogenic properties

Hiroshi Yagi, Masakazu Ueda, Hiromitsu Jinno, Koichi Aiura, Shuji Mikami, Hiroko Tada, Masaharu Seno, Hidenori Yamada, Masaki Kitajima

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

It is thought that the export of angiogenic fibroblast growth factors (FGF) from tumors may be involved in the onset of tumor angiogenesis. To create a new active targeting drug that inhibits the tumor angiogenic process without toxicities to normal cells, human basic FGF (h-bFGF) was inserted genetically into the Gly89 position of cross-linked RNase1 (the ribonuclease inhibitor protein [RI] binding site of cross-linked human pancreatic RNase) to prevent stereospecific binding to RI. The resultant insertional-fusion protein (CL-RFN89) was active both as h-bFGF and as RNase1. Furthermore, it acquired an additional ability of evading RI through steric blockade of RI binding caused by the fused h-bFGF domain. In the present study, the effect of the resultant protein, CL-RFN89, on the antitumor response though its antiangiogenic properties was investigated in an in vivo model. Continuous systemic treatment with CL-RFN89 significantly inhibited the growth of human A431 squamous cell carcinomas in vivo. Seven days of treatment with CL-RFN89 resulted in a 58.2% inhibition of tumor growth compared with control mice (P < 0.0001). Furthermore, immunohistochemistry using a rat antimouse CD31 antibody showed that treatment with CL-RFN89 reduced tumor vascularization. These findings identify CL-RFN89 as a potent systemic inhibitor of tumor growth as a result of its antiangiogenic properties. This protein appears to be a new systemic antitumor agent.

Original languageEnglish
Pages (from-to)1315-1320
Number of pages6
JournalCancer Science
Volume97
Issue number12
DOIs
Publication statusPublished - 2006 Dec

Fingerprint

Pancreatic Ribonuclease
Fibroblast Growth Factor 2
Ribonucleases
Neoplasms
Proteins
Protein Binding
Growth Inhibitors
Fibroblast Growth Factors
Drug Delivery Systems
Growth
Antineoplastic Agents
Squamous Cell Carcinoma
Therapeutics
Immunohistochemistry
Binding Sites
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Anti-tumor effect in an in vivo model by human-derived pancreatic RNase with basic fibroblast growth factor insertional fusion protein through antiangiogenic properties. / Yagi, Hiroshi; Ueda, Masakazu; Jinno, Hiromitsu; Aiura, Koichi; Mikami, Shuji; Tada, Hiroko; Seno, Masaharu; Yamada, Hidenori; Kitajima, Masaki.

In: Cancer Science, Vol. 97, No. 12, 12.2006, p. 1315-1320.

Research output: Contribution to journalArticle

Yagi, Hiroshi ; Ueda, Masakazu ; Jinno, Hiromitsu ; Aiura, Koichi ; Mikami, Shuji ; Tada, Hiroko ; Seno, Masaharu ; Yamada, Hidenori ; Kitajima, Masaki. / Anti-tumor effect in an in vivo model by human-derived pancreatic RNase with basic fibroblast growth factor insertional fusion protein through antiangiogenic properties. In: Cancer Science. 2006 ; Vol. 97, No. 12. pp. 1315-1320.
@article{76a1aaeeefc14045a6219e833644c795,
title = "Anti-tumor effect in an in vivo model by human-derived pancreatic RNase with basic fibroblast growth factor insertional fusion protein through antiangiogenic properties",
abstract = "It is thought that the export of angiogenic fibroblast growth factors (FGF) from tumors may be involved in the onset of tumor angiogenesis. To create a new active targeting drug that inhibits the tumor angiogenic process without toxicities to normal cells, human basic FGF (h-bFGF) was inserted genetically into the Gly89 position of cross-linked RNase1 (the ribonuclease inhibitor protein [RI] binding site of cross-linked human pancreatic RNase) to prevent stereospecific binding to RI. The resultant insertional-fusion protein (CL-RFN89) was active both as h-bFGF and as RNase1. Furthermore, it acquired an additional ability of evading RI through steric blockade of RI binding caused by the fused h-bFGF domain. In the present study, the effect of the resultant protein, CL-RFN89, on the antitumor response though its antiangiogenic properties was investigated in an in vivo model. Continuous systemic treatment with CL-RFN89 significantly inhibited the growth of human A431 squamous cell carcinomas in vivo. Seven days of treatment with CL-RFN89 resulted in a 58.2{\%} inhibition of tumor growth compared with control mice (P < 0.0001). Furthermore, immunohistochemistry using a rat antimouse CD31 antibody showed that treatment with CL-RFN89 reduced tumor vascularization. These findings identify CL-RFN89 as a potent systemic inhibitor of tumor growth as a result of its antiangiogenic properties. This protein appears to be a new systemic antitumor agent.",
author = "Hiroshi Yagi and Masakazu Ueda and Hiromitsu Jinno and Koichi Aiura and Shuji Mikami and Hiroko Tada and Masaharu Seno and Hidenori Yamada and Masaki Kitajima",
year = "2006",
month = "12",
doi = "10.1111/j.1349-7006.2006.00336.x",
language = "English",
volume = "97",
pages = "1315--1320",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Anti-tumor effect in an in vivo model by human-derived pancreatic RNase with basic fibroblast growth factor insertional fusion protein through antiangiogenic properties

AU - Yagi, Hiroshi

AU - Ueda, Masakazu

AU - Jinno, Hiromitsu

AU - Aiura, Koichi

AU - Mikami, Shuji

AU - Tada, Hiroko

AU - Seno, Masaharu

AU - Yamada, Hidenori

AU - Kitajima, Masaki

PY - 2006/12

Y1 - 2006/12

N2 - It is thought that the export of angiogenic fibroblast growth factors (FGF) from tumors may be involved in the onset of tumor angiogenesis. To create a new active targeting drug that inhibits the tumor angiogenic process without toxicities to normal cells, human basic FGF (h-bFGF) was inserted genetically into the Gly89 position of cross-linked RNase1 (the ribonuclease inhibitor protein [RI] binding site of cross-linked human pancreatic RNase) to prevent stereospecific binding to RI. The resultant insertional-fusion protein (CL-RFN89) was active both as h-bFGF and as RNase1. Furthermore, it acquired an additional ability of evading RI through steric blockade of RI binding caused by the fused h-bFGF domain. In the present study, the effect of the resultant protein, CL-RFN89, on the antitumor response though its antiangiogenic properties was investigated in an in vivo model. Continuous systemic treatment with CL-RFN89 significantly inhibited the growth of human A431 squamous cell carcinomas in vivo. Seven days of treatment with CL-RFN89 resulted in a 58.2% inhibition of tumor growth compared with control mice (P < 0.0001). Furthermore, immunohistochemistry using a rat antimouse CD31 antibody showed that treatment with CL-RFN89 reduced tumor vascularization. These findings identify CL-RFN89 as a potent systemic inhibitor of tumor growth as a result of its antiangiogenic properties. This protein appears to be a new systemic antitumor agent.

AB - It is thought that the export of angiogenic fibroblast growth factors (FGF) from tumors may be involved in the onset of tumor angiogenesis. To create a new active targeting drug that inhibits the tumor angiogenic process without toxicities to normal cells, human basic FGF (h-bFGF) was inserted genetically into the Gly89 position of cross-linked RNase1 (the ribonuclease inhibitor protein [RI] binding site of cross-linked human pancreatic RNase) to prevent stereospecific binding to RI. The resultant insertional-fusion protein (CL-RFN89) was active both as h-bFGF and as RNase1. Furthermore, it acquired an additional ability of evading RI through steric blockade of RI binding caused by the fused h-bFGF domain. In the present study, the effect of the resultant protein, CL-RFN89, on the antitumor response though its antiangiogenic properties was investigated in an in vivo model. Continuous systemic treatment with CL-RFN89 significantly inhibited the growth of human A431 squamous cell carcinomas in vivo. Seven days of treatment with CL-RFN89 resulted in a 58.2% inhibition of tumor growth compared with control mice (P < 0.0001). Furthermore, immunohistochemistry using a rat antimouse CD31 antibody showed that treatment with CL-RFN89 reduced tumor vascularization. These findings identify CL-RFN89 as a potent systemic inhibitor of tumor growth as a result of its antiangiogenic properties. This protein appears to be a new systemic antitumor agent.

UR - http://www.scopus.com/inward/record.url?scp=33750358149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750358149&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2006.00336.x

DO - 10.1111/j.1349-7006.2006.00336.x

M3 - Article

C2 - 17032310

AN - SCOPUS:33750358149

VL - 97

SP - 1315

EP - 1320

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 12

ER -